Literature DB >> 28494748

The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder.

Kanit Tha Deang1, Hatta Sidi1, Hazli Zakaria1, Raja Lope Adam1, Srijit Das1, Nurul Hazwani Hatta2, Muhammad Hizri Hatta3, Kok Wei Wee4.   

Abstract

Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involves numerous challenges, which include a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delay the necessary assessment and proper treatment for this debilitating medical disorder. Adult ADHD is often misdiagnosed (or under diagnosed) due to the fact that this medical condition is being masked by the patients' high level of intellectual achievement. As the ADHD in adult persists, it may end-up with impairment in the personal-social-occupational function in which the management becomes a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psycho stimulants like methylphenidate, which is marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. The role of Bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures. This may be of immense benefit to the psychiatrists for treating their patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Bupropion; adult ADHD; novel antidepressants; treatment.

Mesh:

Substances:

Year:  2019        PMID: 28494748     DOI: 10.2174/1389450118666170511145628

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

Review 1.  Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.

Authors:  Asher Ornoy
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

2.  Methylglyoxal-Mediated Dopamine Depletion, Working Memory Deficit, and Depression-Like Behavior Are Prevented by a Dopamine/Noradrenaline Reuptake Inhibitor.

Authors:  Gudrian Ricardo Lopes de Almeida; Jozimar Carlos Szczepanik; Ingrid Selhorst; Ariana Ern Schmitz; Bárbara Dos Santos; Maurício Peña Cunha; Isabella Aparecida Heinrich; Gabriela Cristina de Paula; Andreza Fabro De Bem; Rodrigo Bainy Leal; Alcir Luiz Dafre
Journal:  Mol Neurobiol       Date:  2020-10-04       Impact factor: 5.590

Review 3.  The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review.

Authors:  Asher Ornoy; Gideon Koren
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.